Cargando…

Neoadjuvant chemotherapy reduces the levels of HMGB1 and E-cadherin in patients with breast cancer

This study investigated the changes in serum tumor marker levels in patients with breast cancer (BC) after neoadjuvant chemotherapy (NACT) and their potential as prognostic factors in NACT. A total of 134 consecutive patients with BC treated at our hospital between January 2019 and December 2021 wer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Qingchang, Wang, Xin, Zhu, Rongchen, Liu, Cuicui, Sun, Shanping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491604/ https://www.ncbi.nlm.nih.gov/pubmed/37684327 http://dx.doi.org/10.1038/s41598-023-41836-5

Ejemplares similares

Association of T-cadherin levels with the response to neoadjuvant chemotherapy in locally advanced breast cancer
por: Kong, Dedi, et al.
Publicado: (2017)

Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy
por: Exner, Ruth, et al.
Publicado: (2016)

Levels of Soluble E-Cadherin in Breast, Gastric, and Colorectal Cancers
por: Repetto, Ombretta, et al.
Publicado: (2014)

E‐cadherin deregulation in breast cancer
por: Corso, Giovanni, et al.
Publicado: (2020)

Evaluating the Effectiveness of Neoadjuvant Chemotherapy in Reducing Mastectomy for Women With Breast Cancer
por: Mohiuddin, Jahan J., et al.
Publicado: (2017)

E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements
por: Christgen, Matthias, et al.
Publicado: (2020)

Prognostic value of reduced E-cadherin expression in breast cancer: a meta-analysis
por: Li, Zhan, et al.
Publicado: (2017)

Impact of chemotherapy on the expression of claudins and cadherins in invasive breast cancer
por: Skálová, Helena, et al.
Publicado: (2019)

Hypoxia‐responsive miR‐141–3p is involved in the progression of breast cancer via mediating the HMGB1/HIF‐1α signaling pathway
por: Sun, Shanping, et al.
Publicado: (2020)

The correlation of anxiety and depression levels with response to neoadjuvant chemotherapy in patients with breast cancer
por: Chintamani,, et al.
Publicado: (2011)

Neoadjuvant chemotherapy: practice and thinking for Chinese patients with early breast cancer
por: Wang, Xue-Fei, et al.
Publicado: (2020)

Radiological assessment of neoadjuvant chemotherapy in breast cancer
por: Ollivier, Liliane
Publicado: (2015)

Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer
por: Wang, Huan, et al.
Publicado: (2020)

Prediction of neoadjuvant chemotherapy response in breast cancer
por: Myllys, Maiju
Publicado: (2021)

E-Cadherin as a diagnostic biomarker in breast cancer
por: Singhai, Rajeev, et al.
Publicado: (2011)

N-Cadherin Promotes Motility in Human Breast Cancer Cells Regardless of Their E-Cadherin Expression
por: Nieman, Marvin T., et al.
Publicado: (1999)

Photoacoustic Computed Tomography of Breast Cancer in Response to Neoadjuvant Chemotherapy
por: Lin, Li, et al.
Publicado: (2021)

Progression of Oral Squamous Cell Carcinoma Accompanied with Reduced E-Cadherin Expression but Not Cadherin Switch
por: Hashimoto, Takashi, et al.
Publicado: (2012)

Neoadjuvant chemotherapy in breast cancer significantly reduces number of yielded lymph nodes by axillary dissection
por: Erbes, Thalia, et al.
Publicado: (2014)

Inulin Supplementation Reduces Systolic Blood Pressure in Women with Breast Cancer Undergoing Neoadjuvant Chemotherapy
por: Becerril-Alarcón, Yizel, et al.
Publicado: (2019)

Expression of E-cadherin in pig kidney
por: Lee, Su-Youn, et al.
Publicado: (2013)

SCD5 expression correlates with prognosis and response to neoadjuvant chemotherapy in breast cancer
por: Zhao, Weipeng, et al.
Publicado: (2021)

Atorvastatin reduces serum HMGB1 levels in patients with hyperlipidemia
por: JIN, DAOQUN, et al.
Publicado: (2012)

Platinum-Based Neoadjuvant Chemotherapy for Breast Cancer With BRCA Mutations: A Meta-Analysis
por: Wang, Chang-Jun, et al.
Publicado: (2020)

Contactin-1 Reduces E-Cadherin Expression Via Activating AKT in Lung Cancer
por: Yan, Judy, et al.
Publicado: (2013)

E-cadherin as a prognostic indicator in primary breast cancer
por: Parker, C, et al.
Publicado: (2001)

Significance of E-cadherin expression in triple-negative breast cancer
por: Kashiwagi, S, et al.
Publicado: (2010)

Low frequency of E-cadherin alterations in familial breast cancer
por: Salahshor, Sima, et al.
Publicado: (2001)

E-cadherin is required for metastasis in multiple models of breast cancer
por: Padmanaban, Veena, et al.
Publicado: (2019)

The Autophagy Machinery Contributes to E-cadherin Turnover in Breast Cancer
por: Damiano, Valentina, et al.
Publicado: (2020)

The role of E-Cadherin expression in primary site of breast cancer
por: Karsten, Nora, et al.
Publicado: (2021)

The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant Chemotherapy
por: Straver, M. E., et al.
Publicado: (2010)

Breast Cancer–Related Lymphedema after Neoadjuvant Chemotherapy
por: Kim, Myungsoo, et al.
Publicado: (2015)

Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future
por: Asaoka, Mariko, et al.
Publicado: (2020)

The breast cancer immune microenvironment is modified by neoadjuvant chemotherapy
por: Urueña, Claudia, et al.
Publicado: (2022)

Efficacy Evaluation of Neoadjuvant Chemotherapy in Breast Cancer by MRI
por: Liu, Yongguang, et al.
Publicado: (2022)

Blood serum levels of E-cadherin in patients with colorectal cancer
por: Cepowicz, Dariusz, et al.
Publicado: (2017)

Analysis of Adjuvant Chemotherapy on Pathological Remission of Breast Cancer
por: Jiang, Bing, et al.
Publicado: (2021)

Inhibition of HMGB1 Overcomes Resistance to Radiation and Chemotherapy in Nasopharyngeal Carcinoma
por: Zhu, Xuewei, et al.
Publicado: (2020)

Clinical Implications of iNOS Levels in Triple-Negative Breast Cancer Responding to Neoadjuvant Chemotherapy
por: Jin, Zining, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_2l5sbbd0p64cj1qkok8du37b6t